Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

4(66.7%)

Phase 2

2(33.3%)

6Total

Phase 1(4)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06667960Phase 1Recruiting

Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer

Role: lead

NCT07221513Phase 2Recruiting

Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension

Role: lead

NCT06369298Phase 2Recruiting

Study of JK07 in Patients With Chronic Heart Failure

Role: lead

NCT04210375Phase 1Completed

Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)

Role: lead

NCT05620134Phase 1Active Not Recruiting

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Role: lead

NCT05322616Phase 1Withdrawn

Single-Ascending Dose Study of JK07 in Subjects With HFpEF

Role: lead

All 6 trials loaded